Renishaw ( RNSHF ) on Wednesday named John Shipsey as CFO and executive director, effective April 13. Shipsey brings prior CFO experience from roles at Dyson Ltd., Smiths Group plc, and Featurespace Ltd., and has also held finance and strategy roles at Diageo plc. The company also appointed Sir David Grant as permanent chair with immediate effect for a period of up to two years. More on Renishaw p...
Renishaw ( RNSHF ) on Wednesday named John Shipsey as CFO and executive director, effective April 13. Shipsey brings prior CFO experience from roles at Dyson Ltd., Smiths Group plc, and Featurespace Ltd., and has also held finance and strategy roles at Diageo plc. The company also appointed Sir David Grant as permanent chair with immediate effect for a period of up to two years. More on Renishaw plc Renishaw plc 2026 Q2 - Results - Earnings Call Presentation Renishaw plc (RNSHF) Q2 2026 Earnings Call Transcript Historical earnings data for Renishaw plc Dividend scorecard for Renishaw plc Financial information for Renishaw plc
PM to meet regional leaders to discuss effort to ‘support and sustain ceasefire’ and reopening the strait of Hormuz Middle East crisis – live updates Keir Starmer is travelling to the Gulf to meet leaders in the region to discuss diplomatic efforts to support the ceasefire agreed between the US and Iran. The prime minister’s visit on Wednesday comes hours after a two-week ceasefire was agreed on T...
PM to meet regional leaders to discuss effort to ‘support and sustain ceasefire’ and reopening the strait of Hormuz Middle East crisis – live updates Keir Starmer is travelling to the Gulf to meet leaders in the region to discuss diplomatic efforts to support the ceasefire agreed between the US and Iran. The prime minister’s visit on Wednesday comes hours after a two-week ceasefire was agreed on Tuesday evening, canceling a self-imposed deadline by the US president, Donald Trump, for Iran to surrender or face widespread destruction. Continue reading...
Banca Monte dei Paschi di Siena SpA formally removed ousted Chief Executive Officer Luigi Lovaglio after it had stripped him of his powers for defying the board’s plan to replace him. The lender’s board “decided to unilaterally terminate the labor contract with Luigi Lovaglio as general manager,” it said in a statement Tuesday. The move is a “direct consequence” of the decision two weeks ago to re...
Banca Monte dei Paschi di Siena SpA formally removed ousted Chief Executive Officer Luigi Lovaglio after it had stripped him of his powers for defying the board’s plan to replace him. The lender’s board “decided to unilaterally terminate the labor contract with Luigi Lovaglio as general manager,” it said in a statement Tuesday. The move is a “direct consequence” of the decision two weeks ago to revoke his powers, it said. Read More: Paschi Strips CEO Lovaglio of Power After He Defied Board Lovaglio has been locked in a bitter fight with Monte Paschi’s board for about a month. The governance body wants to replace him with Fabrizio Palermo , an external candidate, while Lovaglio is seeking a new term as a candidate for a Monte Paschi investor, PLT Holding . Shareholders will get to vote on the candidates at the annual general meeting on April 15. Read More: Paschi’s Ousted CEO Lovaglio ‘Confident’ He’ll Get New Term Lovaglio is widely credited with turning around Monte Paschi after assuming the CEO role a little over four years ago. He also pulled off the takeover of rival Mediobanca SpA last year. However, his plan on how to integrate the acquisition has created tensions with some shareholders, people familiar with the matter have said. In addition, he’s facing a judicial probe over that deal, which also involves two powerful Monte Paschi shareholders, construction tycoon Francesco Gaetano Caltagirone and Francesco Milleri , chairman of the holding company Delfin Sarl . All have denied wrongdoing.
sasirin pamai/iStock via Getty Images Investment Summary The core of CorMedix's ( CRMD ) thesis relies on whether the business can soon find its second growth engine. DefenCath, CorMedix's core business, generated $258.8M of revenue in FY25 but is already guided much lower in FY26 due to a reduction in its reimbursement structure, as the TDAPA period for DefenCath is soon coming to an end. The pro...
sasirin pamai/iStock via Getty Images Investment Summary The core of CorMedix's ( CRMD ) thesis relies on whether the business can soon find its second growth engine. DefenCath, CorMedix's core business, generated $258.8M of revenue in FY25 but is already guided much lower in FY26 due to a reduction in its reimbursement structure, as the TDAPA period for DefenCath is soon coming to an end. The problem is, FY25 pro forma revenue (with the recent Melinta acquisition) was $401.3M. Only $142.5M was generated outside of DefenCath. Melinta alone was already generating $120M in FY24, implying that the non-DefenCath business does not yet add much economic weight, and likely not enough to compensate for DefenCath's sharp decline expected in the coming years given management's FY26 and FY27's guidances. Management presents CorMedix as a diversified anti-infective platform with its future growth assets, Rezzayo Prophylaxis and DefenCath TPN (both in stage 3 of clinical trials), but the business' health still largely depends on DefenCath's trajectory. This is not a "buy the transition" story yet, but rather a "show-me story". As of today, the evidence that the rest of the portfolio can offset or reverse DefenCath's decline is still too thin. Business Overview CorMedix is a specialty pharmaceutical company focused on providing anti-infective care to hospitals. Its business is still centered around DefenCath, a dialysis catheter lock solution. They have additional revenue lines from legacy antibiotics, mostly through the acquisition of Melinta. This non-DefenCath bucket includes the current portfolio acquired through Melinta (Rezzayo, a drug used to treat serious fungal infections in the blood, but also Minocin, Vabomere, etc.), but does not yet include Rezzayo Prophylaxis and DefenCath TPN, which are not yet clinically approved. DefenCath was the dominant driver during the TDAPA period (a temporary reimbursement bonus for new drugs in dialysis), which removed economic friction f...
Dougal Waters/DigitalVision via Getty Images Introduction Given its planned separation into a royalty company and another with a development-stage pipeline, AnaptysBio ( ANAB ) now has to be valued as two different businesses. The royalty business, backed by the billion-dollar blockbuster Jemperli, is high-margin, while the biopharma company has rosnilimab, a phase 2b asset in rheumatoid arthritis...
Dougal Waters/DigitalVision via Getty Images Introduction Given its planned separation into a royalty company and another with a development-stage pipeline, AnaptysBio ( ANAB ) now has to be valued as two different businesses. The royalty business, backed by the billion-dollar blockbuster Jemperli, is high-margin, while the biopharma company has rosnilimab, a phase 2b asset in rheumatoid arthritis. Rosnilimab, a selective pathogenic T-cell depleter, demonstrated statistically significant efficacy across multiple endpoints in a 424-patient global RA study. The royalty company will begin life with roughly $140–$145 million in net cash, a low-cost structure, and royalty from Jemperli alone will be around $100 million annualized. Plus it has imsidolimab. First Tracks, the pipeline company, will launch with around $180 million in cash. That brings us to the idea that if the royalty business, with its steady income stream, is supporting a large part of the current market value, then the pipeline isn’t being priced to succeed. However, rosnilimab’s data—particularly the translational evidence connecting targeted T-cell depletion in both blood and synovium with signs of clinical improvement—deserves to be assigned some value. In this article, after looking at the clinical evidence and the competitive landscape, we will run through a valuation framework that separates the royalty business from the pipeline. The Separation The royalty company, management has said, will operate with a minimal annual operating expense of less than $10 million and minimal infrastructure, so it will be a high-margin business. Jemperli has already surpassed $1 billion in annual sales. Imsidolimab, which targets generalized pustular psoriasis (GPP), has a PDUFA on December 12. The NDA is supported by Phase 3 (GEMINI-1/GEMINI-2) data that saw a rapid response where ~53% achieved clear/almost clear skin vs. ~13% placebo at Week 4. GPP is not a large market, and spesolimab (Spevigo) is the only approv...
Plus: teams who went out of Europe without losing a game, and rare competitive meetings Mail us with your questions and answers “What’s the furthest a team has gone in Europe while being relegated in the same season?” wonders Matt Reilly. This question was probably asked in reference to Tottenham, who were still in the Champions League at the time, but it’s still relevant to some of this year’s qu...
Plus: teams who went out of Europe without losing a game, and rare competitive meetings Mail us with your questions and answers “What’s the furthest a team has gone in Europe while being relegated in the same season?” wonders Matt Reilly. This question was probably asked in reference to Tottenham, who were still in the Champions League at the time, but it’s still relevant to some of this year’s quarter-finalists. Nottingham Forest are three points above the relegation places in the Premier League; Fiorentina only have a five-point cushion in Serie A. Real Zaragoza 2001-02, first round; 2007-08, first round Alaves 2002-03, second round Celta Vigo 2006-07, last 16 Real Zaragoza 2007-08, first round Real Betis 2013-14, last 16 Espanyol 2019-20, last 32 Blackburn Rovers 1998-99, Uefa Cup first round Bradford City 2000-01, Intertoto semi-final Ipswich Town 2001-02, Uefa Cup third round Ruda Hvezda Brno 1960-61, Cup Winners’ Cup Dynamo Zilina 1961-62, Cup Winners’ Cup Espanyol 1961-62. Inter-Cities Fairs Cup Napoli 1962-63, Cup Winners’ Cup Bayern Munich 1962-63, Inter-Cities Fairs Cup 1. FC Magdeburg 1965-66, Cup Winners’ Cup Lyn 1968-69, Cup Winners’ Cup Beroe Stara Zagora 1973-74, Cup Winners’ Cup Real Betis 1977-78, Cup Winners’ Cup Bologna 1990-91, Uefa Cup First round Artmedia Bratislavia (2-2 away, 3-1 home) Group stage Sparta Prague (2-0 away), Zulte Waregem (6-2 home), Ajax (2-0 away), Austria Wien (1-0 home) Last 32 Livorno (2-1 away, 2-0 home) Last 16 Maccabi Haifa (0-0 away, 4-0 home) Quarter-final Benfica (3-2 home, 0-0 away) Semi-final Werder Bremen (3-0 home, 2-1 away) Final Sevilla 2-2 (1-3 pens) Continue reading...
Sing believes her ‘farm strength’ can help her compete with Red Roses star to become England’s starting full-back Emma Sing has ambitions to become England’s starting full-back in the Six Nations, but insists there is no rivalry between her and Ellie Kildunne, the Red Roses’ breakout World Cup star. Sing is a Rugby World Cup winner, a multiple Six Nations grand slam champion and has lifted the Pre...
Sing believes her ‘farm strength’ can help her compete with Red Roses star to become England’s starting full-back Emma Sing has ambitions to become England’s starting full-back in the Six Nations, but insists there is no rivalry between her and Ellie Kildunne, the Red Roses’ breakout World Cup star. Sing is a Rugby World Cup winner, a multiple Six Nations grand slam champion and has lifted the Premiership Women’s Rugby trophy three times. Touting her achievements is not something the Gloucester-Hartpury back is comfortable with, but the silverware, along with her consistent club performances, are the reason why the 25-year-old is pushing for a starting place. Continue reading...
We have put together stories from our coverage on science from the past two weeks to help you stay informed. If you would like to see more of our reporting, please consider subscribing. 1. Chinese embassy in US confirms death of semiconductor researcher Wang Danhao Chinese semiconductor researcher Wang Danhao died at the University of Michigan last month, shortly after being questioned by US feder...
We have put together stories from our coverage on science from the past two weeks to help you stay informed. If you would like to see more of our reporting, please consider subscribing. 1. Chinese embassy in US confirms death of semiconductor researcher Wang Danhao Chinese semiconductor researcher Wang Danhao died at the University of Michigan last month, shortly after being questioned by US federal law enforcement. 2. ‘Impossible for Chinese’: Yale scientist Zhang Kai leaves US for China Zhang...
Ramberg/E+ via Getty Images France recorded a trade deficit of €5.8B in February of 2026, much wider than estimates. The increase in imports was driven by higher imports of natural hydrocarbons, transport equipment, and pharmaceuticals, particularly from China. The decline in exports is explained by a marked decrease in electricity exports and aerospace industry products. More on France U.S. Tarif...
Ramberg/E+ via Getty Images France recorded a trade deficit of €5.8B in February of 2026, much wider than estimates. The increase in imports was driven by higher imports of natural hydrocarbons, transport equipment, and pharmaceuticals, particularly from China. The decline in exports is explained by a marked decrease in electricity exports and aerospace industry products. More on France U.S. Tariffs: A New Trade War? EWQ: Falling Real Rates Delayed The Bear Case, But 2026 May Not European markets mixed as rising oil and war risks cloud outlook Germany's service sector growth slows sharply in March Seeking Alpha’s Quant Rating on iShares MSCI France ETF
Riley Exploration Permian (REPX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Riley Exploration Permian (REPX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.